O'Leary Daniel H, Polak Joseph F
Department of Radiology, Tufts New England Medical Center, Boston, Massachusetts, USA.
Am J Cardiol. 2002 Nov 21;90(10C):18L-21L. doi: 10.1016/s0002-9149(02)02957-0.
Multiple studies have shown that the carotid artery intima-media thickness (IMT), as measured noninvasively by ultrasonography, is directly associated with an increased risk of cardiovascular disease. Because it has been shown to be an independent predictor of cardiovascular disease after adjustment for traditional risk factors, it is the only noninvasive imaging test currently recommended by the American Heart Association for inclusion in the evaluation of risk. However, it remains unclear how much additional information beyond that afforded by traditional risk factors is gained by inclusion of IMT in risk profiles. Change in IMT is increasingly being used as the end point in interventional trials. Meaningful differences in progression rates have been shown in progression rates in trials of either lipid-lowering drugs or calcium channel blockers involving several hundred subjects over a period of several years. Acceptance of a standardized protocol for measuring IMT change would facilitate comparison of results from the many trials using this technique. However, uncertainty about which measure of IMT offers the best end point has inhibited methodologic standardization.
多项研究表明,通过超声检查无创测量的颈动脉内膜中层厚度(IMT)与心血管疾病风险增加直接相关。由于在对传统风险因素进行调整后,它已被证明是心血管疾病的独立预测指标,因此它是美国心脏协会目前推荐纳入风险评估的唯一无创成像检查。然而,目前尚不清楚将IMT纳入风险评估中,除了传统风险因素所提供的信息之外,还能获得多少额外信息。IMT的变化越来越多地被用作干预试验的终点。在涉及数百名受试者、为期数年的降脂药物或钙通道阻滞剂试验中,已显示出进展率存在有意义的差异。接受用于测量IMT变化的标准化方案将有助于比较使用该技术的众多试验的结果。然而,关于哪种IMT测量方法能提供最佳终点的不确定性阻碍了方法学的标准化。